The clinical significance of MDSC levels for CRC outcomes was demonstrated by studies showing elevated CD33+ MDSC cells in CRC patients were associated with significantly reduced disease-free and overall survival [82]. The gene discussed is CD33; the disease is colorectal carcinoma.